{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:37:09Z","timestamp":1777934229597,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T00:00:00Z","timestamp":1400457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:p>\n                    Hodgkin lymphoma is a curable disease in the vast majority of cases with a cure rate approaching 85 to 95% with initial therapy. However, some patients experience relapse and in patients with relapsed\/refractory disease, prognosis remains poor and active agents are needed in this setting. Bendamustine is an alkylating agent with clinical activity against various lymphomas including follicular, mantle, diffuse large B cell lymphoma, and chronic lymphocytic leukemia; however, its activity in Hodgkin lymphoma is not yet well established. We report a case of a 55-year-old man with relapsed Hodgkin lymphoma that is heavily pretreated and was successfully treated with four cycles of single agent bendamustine (90 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) with complete response after two cycles and without any significant toxicity. These findings suggest that bendamustine is highly active in Hodgkin lymphoma.\n                  <\/jats:p>","DOI":"10.1177\/1078155214535826","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T21:31:08Z","timestamp":1400621468000},"page":"309-311","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient"],"prefix":"10.1177","volume":"20","author":[{"given":"Raymond","family":"Elsoueidi","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Appalachian Regional Healthcare (ARH), Hazard, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alem","family":"Mulat","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hazard ARH Regional Medical Center, Hazard, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham","family":"Mourad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hazard ARH Regional Medical Center, Hazard, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,5,19]]},"reference":[{"key":"bibr1-1078155214535826","unstructured":"Bendamustine. Lexi-Drugs Online. Lexi-Comp, Inc. (accessed 2 August 2013)."},{"key":"bibr2-1078155214535826","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.031"},{"key":"bibr3-1078155214535826","doi-asserted-by":"crossref","unstructured":"De Filippi R, Aldinucci D, Galati D, et\u00a0al. Effect of Bendamustine on apoptosis and colony \u2013 intiating precursors in Hodgkin lymphoma cells.\n                      J Clin Oncol\n                      2011; 29(supp): abst e 18559.","DOI":"10.1200\/jco.2011.29.15_suppl.e18559"},{"key":"bibr4-1078155214535826","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/9.suppl_5.S103"},{"key":"bibr5-1078155214535826","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"bibr6-1078155214535826","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.776165"},{"key":"bibr7-1078155214535826","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.06.011"},{"key":"bibr8-1078155214535826","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1525-z"},{"key":"bibr9-1078155214535826","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12548"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155214535826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155214535826","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155214535826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:15:42Z","timestamp":1777688142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155214535826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,19]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1177\/1078155214535826"],"URL":"https:\/\/doi.org\/10.1177\/1078155214535826","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,19]]}}}